MYH14 and microscopic polyangiitis: Although it is elusive whether anti-MYL6 antibody is exactly associated with good prognosis because MPA patients in the RemIT-JAV-RPGN cohort received diverse treatment, the association of NET formation inhibitory potential of anti-MYL6 antibody and the low activity scores of cutaneous, cardiovascular, and nervous system lesions in anti-MYL6 antibody-positive MPA patients before treatment is suggestive of an involvement of the myosin and F-actin interaction in NET formation leading to the development of these lesions.